杰龙 GERN 深 沪
已收盘 03-27 16:00:00 美东时间
1.40
-0.140
-9.09%
华盛通- 最 高1.54
- 今 开1.51
- 成交量 1924.90万股
- 最 低 1.40
- 昨 收 1.54
- 总市值 8.97亿
- 52周最高 2.01
- 市盈率 静 --
- 换手率 3.01%
- 52周最低 1.04
- 委 比 37.60%
- 总股本 6.41亿
- 历史最高 7.79
- 量 比 0.87
- 振 幅 9.09%
- 历史最低 0.75
- 每 手 1
- 风险率 0.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Geron Announces Appointment of New Members to its Board of Directors
Geron Corporation announced the appointment of Patricia S. Andrews and Constantine Chinoporos to its Board of Directors. Both bring extensive experience in the biopharmaceutical industry, particularly in commercial-stage organizations. Their expertise will support Geron's strategic priorities and the commercial growth of RYTELO<sup>®</sup>, a treatment for lower-risk myelodysplastic syndromes/neoplasms (LR-MDS). Andrews and Chinoporos have held s...
03-26 12:00
新浪财经ESG：杰龙 MSCI（明晟）ESG评级调降至BB
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
03-24 10:21
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>Geron Corporation granted stock options for 956,250 shares to six new employees, priced at $1.62 per share, vesting over four years with a 10-year term. The equity awards comply with Nasdaq Listing Rule 5635(c)(4) under the 2018 Inducement Award Plan. Geron is a biopharmaceutical company focused on blood cancer treatments, including RYTELO® for myelodysplastic syndromes and a Phase 3 trial for myelofibrosis.</p>
03-18 20:05
Geron shares are trading lower after the company reported worse-than-expected Q4 financial results.
Geron shares are trading lower after the company reported worse-than-expected Q...
02-26 01:18
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Larimar Therapeutics (NASDAQ:LRMR) shares moved upwards by 58.4% to $5...
02-26 01:05
Geron falls as Q4 results miss expectations
Shares of Geron Corporation (GERN) lost ~15% in the premarket on Wednesday after the cancer drug developer missed Street forecasts with its Q4 2025 results and reaffirmed its full-year outlook. The ma...
02-25 22:25
Geron Corporation Publishes Corporate Presentation on RYTELO Imatelstat and Lower-Risk Myelodysplastic Syndromes
Geron Corporation Publishes Corporate Presentation on RYTELO Imatelstat and Lower-Risk Myelodysplastic Syndromes Geron Corporation released a corporate presentation outlining its plans for RYTELO (imetelstat), a telomerase inhibitor approved in the U.S. and EU for certain adults with lower-risk myel
02-25 21:34
Earnings Scheduled For February 25, 2026
Companies Reporting Before The Bell • Clear Secure (NYSE:YOU) is expected to re...
02-25 19:11
Geron Plans to Present at Upcoming Investor Conferences
Geron Corporation announced that its management team will present at three investor conferences: the TD Cowen 46th Annual Healthcare Conference on March 2 in Boston, the Barclays 28th Annual Global Healthcare Conference on March 10 in Miami, and the Leerink Partners Global Healthcare Conference on March 11 in Miami. A live and archived audio webcast of each fireside chat will be available on Geron’s website. Geron is a biopharmaceutical company f...
02-23 13:00
